Andrea Wang-Gillam

Company: Jacobio Pharmaceuticals Inc

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Reviewing the Toxicity Concerns with Multi-Inhibitors & Strategies to Pre-Emptively Address Them 11:15 am

PAN-RAS inhibitors are known to be mutations and often isofrom agnostic. Due to their unique mechanisms of action, they often target wild-type RAS as well, resulting in normal cell toxicity. Preemptively dealing with these foreseen negative effects is important to ensure that PAN-inhibitors and multi-inhibitors can reach their full potential as personalized cancer treatments. Reviewing…Read more

day: Day Two Track B AM